Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 13/20 | 0.71 |
| ▸ | PDE2A | O00408 | 4/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124199 | 0.84 | EPHB3 (0.59) | EPHB3RIPK2LCKJAK2CYP1A2 | |
| SCHEMBL2873995 | 0.77 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL18208186 | 0.75 | PDE2A (0.49) | EPHB3PDE2A | |
| SCHEMBL18208182 | 0.75 | PDE2A (0.49) | EPHB3PDE2A | |
| SCHEMBL22170113 | 0.74 | EPHB3 (1.00) | EPHB3RIPK2LCK | |
| SCHEMBL21326698 | 0.74 | PDE2A (0.53) | PDE2A | |
| SCHEMBL22640640 | 0.74 | IRAK4 (0.66) | EPHB3RIPK2LCKJAK2 | |
| SCHEMBL18208224 | 0.74 | PDE2A (0.48) | PDE2AJAK2HPGD | |
| SCHEMBL18208227 | 0.74 | PDE2A (0.48) | PDE2AJAK2HPGD | |
| SCHEMBL310126 | 0.74 | PDE2A (0.59) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | EPHB3 3762/4885PDE2A 2965/4885RIPK2 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.